Table 2.
Progression risk from CN and MCI.
| Stage | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|
| Progression to CDR-GS ≥ 0.5 from CN | ||||
| Stage 2 | Reference | / | / | / |
| Stage 3 | 3.29 (1.09, 9.97) | 3.53 × 10−2 | Reference | / |
| Stage 4 | 18.7 (3.46,100.9) | 6.64 × 10−4 | 4.99 (0.96, 25.8) | 5.53 × 10−2 |
| Progression to progressive cognitive deterioration from MCI | ||||
| Stage 2 | Reference | / | / | / |
| Stage 3 | 4.23 (1.68,10.6) | 2.20 × 10−3 | Reference | / |
| Stage 4 | 8.99 (2.77,29.1) | 2.54 × 10−4 | 1.92 (0.79, 4.68) | 0.15 |
CI confidence interval, CN cognitively normal, MCI mild cognitive impairment, CDR-GS clinical dementia rating– global score.
Progressive cognitive deterioration defined as (1) diagnosis of dementia or (2) MMSE ≤ 24 at last visit or (3) difference of MMSE ≥ 4 between the first visit and the last visit.
Hazard ratios (95% CI) were calculated using Cox regression analyses and corrected for baseline age, gender, years of education and ApoE ε4 counts. Stage 0 and stage 1 were not included in analyses for no events occurred in follow-up.